Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced CEO John P. Butler will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. This virtual event will provide insights about the company’s mission and ongoing developments. A recorded version of the presentation will be available on the company’s investor website starting March 9. Akebia, founded in 2007 and based in Cambridge, Massachusetts, aims to improve the lives of those affected by kidney disease.
- None.
- None.
CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer of Akebia, will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, which takes place virtually March 9-10, 2021.
The recorded presentation will be available on the Investors section of the Company's website at https://ir.akebia.com beginning Tuesday, March 9.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-global-life-sciences-conference-301237797.html
SOURCE Akebia Therapeutics
FAQ
What is Akebia Therapeutics' stock symbol?
When will John P. Butler speak at the H.C. Wainwright Global Life Sciences Conference?
Where can I watch the Akebia conference presentation?
What is the purpose of Akebia Therapeutics?
